Literature DB >> 25173393

Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE).

Annie C Bowles1, Brittni A Scruggs, Bruce A Bunnell.   

Abstract

Multiple sclerosis (MS) is a common neurodegenerative disease that presents after an auto-reactive immune response against constituents of the central nervous system. Demyelination, inflammation, and white matter lesions are all hallmarks of this disease. Clinical research supports the use of mesenchymal stem cells (MSCs) as therapy for MS to ameliorate symptoms and pathology. MSCs can be isolated from multiple tissues, including adipose and bone marrow, and are able to migrate to sites of pathology, release anti-inflammatory factors, and provide immunomodulatory and neuroprotective effects once administered. Numerous studies have demonstrated the beneficial effects of MSCs in experimental autoimmune encephalomyelitis (EAE), an induced model of MS. EAE can be induced in several species; however, the mouse is commonly used for therapeutic testing. In the following chapter, scientists will be able to learn how to prepare reagents and MSCs (e.g., isolate, culture, and expand) as well as skillfully execute induction of EAE in mice and administer stem cell-based treatments. Standard methods used to evaluate the disease progression and analyze postmortem tissues are also included.

Entities:  

Mesh:

Year:  2014        PMID: 25173393      PMCID: PMC4372385          DOI: 10.1007/978-1-4939-1453-1_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  Multiple sclerosis review.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2012-03

Review 2.  Mesenchymal stem cells as treatment for MS - progress to date.

Authors:  Antonio Uccelli; Alice Laroni; Mark S Freedman
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

3.  Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model.

Authors:  Brittni A Scruggs; Julie A Semon; Xiujuan Zhang; Shijia Zhang; Annie C Bowles; Amitabh C Pandey; Kathleen M P Imhof; Allan V Kalueff; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells Transl Med       Date:  2013-09-09       Impact factor: 6.940

4.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

Authors:  Emanuela Zappia; Simona Casazza; Enrico Pedemonte; Federica Benvenuto; Ivan Bonanni; Ezio Gerdoni; Debora Giunti; Antonella Ceravolo; Francesco Cazzanti; Francesco Frassoni; Gianluigi Mancardi; Antonio Uccelli
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

Review 5.  The molecular basis of neurodegeneration in multiple sclerosis.

Authors:  Hans Lassmann; Jack van Horssen
Journal:  FEBS Lett       Date:  2011-08-16       Impact factor: 4.124

6.  Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Authors:  Dimitrios Karussis; Clementine Karageorgiou; Adi Vaknin-Dembinsky; Basan Gowda-Kurkalli; John M Gomori; Ibrahim Kassis; Jeff W M Bulte; Panayiota Petrou; Tamir Ben-Hur; Oded Abramsky; Shimon Slavin
Journal:  Arch Neurol       Date:  2010-10

Review 7.  Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm.

Authors:  Helena Batoulis; Klaus Addicks; Stefanie Kuerten
Journal:  Ann Anat       Date:  2010-07-15       Impact factor: 2.698

8.  Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis.

Authors:  Gabriela Constantin; Silvia Marconi; Barbara Rossi; Stefano Angiari; Laura Calderan; Elena Anghileri; Beatrice Gini; Simone Dorothea Bach; Marianna Martinello; Francesco Bifari; Mirco Galiè; Ermanna Turano; Simona Budui; Andrea Sbarbati; Mauro Krampera; Bruno Bonetti
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

9.  High-throughput screening of stem cell therapy for globoid cell leukodystrophy using automated neurophenotyping of twitcher mice.

Authors:  Brittni A Scruggs; Annie C Bowles; Xiujuan Zhang; Julie A Semon; Evan J Kyzar; Leann Myers; Allan V Kalueff; Bruce A Bunnell
Journal:  Behav Brain Res       Date:  2012-08-20       Impact factor: 3.332

Review 10.  Progressive multiple sclerosis: pathology and pathogenesis.

Authors:  Hans Lassmann; Jack van Horssen; Don Mahad
Journal:  Nat Rev Neurol       Date:  2012-09-25       Impact factor: 42.937

View more
  10 in total

1.  Induction of CD4+CD25+Foxp3+ regulatory T cells by mesenchymal stem cells is associated with RUNX complex factors.

Authors:  Maryam Khosravi; Ali Bidmeshkipour; Ali Moravej; Suzzan Hojjat-Assari; Sina Naserian; Mohammad Hossein Karimi
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 2.  Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis.

Authors:  Mohammadmahdi Jafarzadeh Bejargafshe; Mohammad Hedayati; Sahar Zahabiasli; Eisa Tahmasbpour; Saeed Rahmanzadeh; Amir Nejad-Moghaddam
Journal:  Stem Cell Investig       Date:  2019-12-27

3.  The orphan ligand, activin C, signals through activin receptor-like kinase 7.

Authors:  Erich J Goebel; Luisina Ongaro; Emily C Kappes; Kylie Vestal; Elitza Belcheva; Roselyne Castonguay; Ravindra Kumar; Daniel J Bernard; Thomas B Thompson
Journal:  Elife       Date:  2022-06-23       Impact factor: 8.713

4.  Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis.

Authors:  Oriana Trubiani; Sabrina Giacoppo; Patrizia Ballerini; Francesca Diomede; Adriano Piattelli; Placido Bramanti; Emanuela Mazzon
Journal:  Stem Cell Res Ther       Date:  2016-01-04       Impact factor: 6.832

5.  Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results.

Authors:  Adam Stepien; Natalia L Dabrowska; Marzena Maciagowska; Renata Piusinska Macoch; Aleksandra Zolocinska; Slawomir Mazur; Katarzyna Siennicka; Emilia Frankowska; Rafał Kidzinski; Małgorzata Chalimoniuk; Zygmunt Pojda
Journal:  Mediators Inflamm       Date:  2016-09-28       Impact factor: 4.711

Review 6.  Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.

Authors:  Asma Alanazi; Mohammad Alassiri; Dunia Jawdat; Yaser Almalik
Journal:  Regen Ther       Date:  2022-08-23       Impact factor: 3.651

Review 7.  The use of patient-specific stem cells in different autoimmune diseases.

Authors:  Zuhair M Mohammedsaleh
Journal:  Saudi J Biol Sci       Date:  2022-02-10       Impact factor: 4.052

8.  Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors.

Authors:  Mei Wu; Hongfeng Ge; Shue Li; Hailiang Chu; Shili Yang; Xiaoxing Sun; Zhenxia Zhou; Xiongpeng Zhu
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

9.  Induction of CD4+CD25+FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation.

Authors:  Maryam Khosravi; Ali Bidmeshkipour; José L Cohen; Ali Moravej; Suzzan Hojjat-Assari; Sina Naserian; Mohammad Hossein Karimi
Journal:  Stem Cell Res Ther       Date:  2018-10-25       Impact factor: 6.832

10.  Evaluation of Differential Gene Expression during Transdifferentiation of Bone Marrow Stromal Cells to Glial Phenotype in the Presence of Cerebrospinal Fluid.

Authors:  Hatef Ghasemi Hamidabadi; Maryam Nazm Bojnordi; Nourollah Rezaei; Sara Soleimani
Journal:  Avicenna J Med Biotechnol       Date:  2019 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.